Effects of Omalizumab in Non-Atopic Asthma: Results from a Spanish Multicenter Registry

  title={Effects of Omalizumab in Non-Atopic Asthma: Results from a Spanish Multicenter Registry},
  author={Luis P{\'e}rez de Llano and Mar{\'i}a del Carmen Vennera and Francisco J. {\'A}lvarez and Juan Francisco Medina and Luis Border{\'i}as and Concepci{\'o}n Pellicer and H{\'e}ctor Gonz{\'a}lez and Jos{\'e} Antonio Gull{\'o}n and Eva Mart{\'i}nez-Morag{\'o}n and Carlos Sabadell and Soledad Zamarro and C{\'e}sar Picado},
  journal={Journal of Asthma},
  pages={296 - 301}
Aim. To evaluate the effectiveness of omalizumab in non-atopic asthma. Methods. Using data from a multicenter registry of severe asthma, we evaluated and compared the clinical outcome of 29 omalizumab-treated severe non-atopic asthmatics with 266 omalizumab-treated severe allergic asthmatics. Effectiveness was assessed by considering severe exacerbations, pulmonary function, the Global Evaluation of Treatment Effectiveness (GETE) scale, and Asthma Control Test (ACT). Results. Omalizumab… 

Severe non-atopic asthma: omalizumab can reduce severe asthma exacerbations.

Omalizumab was effective in severe asthma, regardless of atopic status, and similar reduction of severe exacerbation rates were observed in T2-low asthma subgroup (non-atopic, non-eosinophilic).

The efficacy of omalizumab treatment in patients with non-atopic severe asthma

In the atopic severe asthma patient group omalizumab treatment provided similar clinical benefits to those observed in patients with severe atopic asthma, suggesting that it may be a useful therapeutic option in Patients with non-atopic asthma who failed to benefit from step 4 and step 5 treatments.

Therapeutic Effect of Omalizumab in Severe Asthma: A Real-World Study in Korea

Omalizumab can reduce exacerbations/hospitalization/systemic steroid burst in Korean adult patients with severe asthma and identify predictors of favorable response.

Omalizumab in non-allergic Asthma: A report of 13 cases

Omalizumab can be effective in non-atopic severe asthma and should be considered as a first-line treatment for patients with non-allergic asthma.

Cost-Effectiveness Analysis of Omalizumab for the Treatment of Severe Persistent Asthma in Real Clinical Practice in Spain

The results of this study confirm the effectiveness of the addition of omalizumab to standard therapy in patients with uncontrolled severe persistent asthma.

Use of Omalizumab as Treatment in Patients with Moderate and Severe Non-Atopic Asthma and Associated with Asthma- COPD Overlap Syndrome (ACOS)

The use of omalizumab therapy reduces IgE expression and IgE sensiti zation of target cells within the bronchial mucosa while exerting a favorable effect on lung function in the short term, as assessed by changes in forced expiratory volume in 1 s (FEV1).

Effect of omalizumab as add-on therapy to Quality of Life Questionnaire for Korean Asthmatics (KAQLQ) in Korean patients with severe persistent allergic asthma

Omalizumab can be considered a biological treatment for Korean patients with severe allergic asthma and is recommended to consider as add-on therapy in patients with high baseline total IgE levels and severe asthma symptoms.

Novel targets of omalizumab in asthma

Omalizumab may have an antiviral effect when used as a preventive therapy for fall exacerbations in children and teenagers and may have corticosteroid-sparing effect in a subset of patients with eosinophilic granulomatosis with polyangiitis.

Omalizumab for Severe Asthma: Efficacy Beyond the Atopic Patient?

The author justifies his belief that omalizumab is not only an IgE-blocking drug and should be considered as a disease-modifying therapy because of its multiple effects on different biologic pathways.



Omalizumab Therapy in Severe Asthma: Experience from the Spanish Registry—Some New Approaches

This real-life study confirms that omalizumab is very efficacious and very well tolerated in patients with uncontrolled severe asthma.

Long-term benefits of omalizumab in a patient with severe non-allergic asthma

This case shows, after a long follow-up, how omalizumab can be effective in a severe form of non-atopic asthma and it is therefore hoped that further studies can identify indicators that are able to give to clinicians information about patients who can be responsive to monoclonal anti-IgE antibody even if non allergic.

[A case of severe asthma responsive to omalizumab treatment despite a low serum IgE level and lack of sensitized allergens].

This case strongly suggests the therapeutic effect of omalizumab in the treatment of severe intractable asthma with low serum IgE level without identifiable allergens.

The ENFUMOSA cross-sectional European multicentre study of the clinical phenotype of chronic severe asthma

It is suggested that severe asthma might be a different form of asthma rather than an increase in asthma symptoms, and longitudinal studies and interventions are needed to define the mechanisms in severe asthma.

Italian real-life experience of omalizumab.

Relationships between Severity of Chronic Rhinosinusitis and Nasal Polyposis, Asthma, and Atopy

It is suggested that CRS is an inflammatory disease that occurs independently of systemic IgE-mediated pathways and chronic airway inflammatory diseases, asthma, and NPs, and the association between LMS and atopic status appears weak.